2018
A Phase I Dose‐Escalation Study of Clofarabine in Patients with Relapsed or Refractory Low‐Grade or Intermediate‐Grade B‐Cell or T‐Cell Lymphoma
Foss FM, Parker T. A Phase I Dose‐Escalation Study of Clofarabine in Patients with Relapsed or Refractory Low‐Grade or Intermediate‐Grade B‐Cell or T‐Cell Lymphoma. The Oncologist 2018, 23: 397-e30. PMID: 29438091, PMCID: PMC5896711, DOI: 10.1634/theoncologist.2017-0658.Peer-Reviewed Original ResearchConceptsCutaneous T-cell lymphomaT-cell lymphomaNon-Hodgkin lymphomaOverall response rateIntermediate-grade B-cellB cellsPartial responseResponse ratePhase I dose-escalation studyRefractory acute lymphoblastic leukemiaI dose-escalation studyT-cell non-Hodgkin lymphomaB-cell non-Hodgkin lymphomaPositron emission tomography scanSecond-generation purine nucleoside analogAggressive B-cell lymphomasPhase IDose of clofarabineGrade 3 leukopeniaLow-dose cohortMinimal hematologic toxicityRefractory acute leukemiaRefractory low gradeRefractory lymphoid malignanciesSingle-agent rituximab
2011
Chronic lymphocytic leukemia: prognostic factors and impact on treatment.
Parker TL, Strout MP. Chronic lymphocytic leukemia: prognostic factors and impact on treatment. Discovery Medicine 2011, 11: 115-23. PMID: 21356166.Peer-Reviewed Original ResearchConceptsChronic lymphocytic leukemiaPrognostic markerBiology of CLLClinical staging systemStandard chemotherapy regimensObvious survival advantageSymptomatic leukemiaChemotherapy regimensMature B cellsPrognostic factorsProlong survivalIndolent diseaseStaging systemClinical managementImmediate treatmentDisease progressionEarly treatmentLymphocytic leukemiaSurvival advantageAggressive formB cellsClinical heterogeneityClonal malignancyEarly interventionPatients